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ABSTRACT
Objectives: To describe demographic features,
assessment, management and outcomes of patients
who were diagnosed with heart failure after presenting
to an emergency department (ED) with a principal
symptom of dyspnoea.
Design: Planned substudy of the prospective,
descriptive cohort study: Asia, Australia and New Zealand
Dyspnoea in Emergency Departments (AANZDEM).
Setting: 46 EDs in Australia, New Zealand, Singapore,
Hong Kong and Malaysia collected data over 3 72-hour
periods in May, August and October 2014.
Participants: Patients with an ED diagnosis of heart
failure.
Outcome measures: Outcomes included patient
epidemiology, investigations ordered, treatment
modalities used and patient outcomes (hospital length
of stay (LOS) and mortality).
Results: 455 (14.9%) of the 3044 patients had an ED
diagnosis of heart failure. Median age was 79 years,
half were male and 62% arrived via ambulance. 392
(86%) patients were admitted to hospital. ED diagnosis
was concordant with hospital discharge diagnosis in
81% of cases. Median hospital LOS was 6 days (IQR
4–9) and in-hospital mortality was 5.1%. Natriuretic
peptide levels were ordered in 19%, with lung
ultrasound (<1%) and echocardiography (2%)
uncommonly performed. Treatment modalities included
non-invasive ventilation (12%), diuretics (73%),
nitrates (25%), antibiotics (16%), inhaled β-agonists
(13%) and corticosteroids (6%).
Conclusions: In the Asia Pacific region, heart failure is
a common diagnosis among patients presenting to the
ED with a principal symptom of dyspnoea. Admission
rates were high and ED diagnostic accuracy was good.
Despite the seemingly suboptimal adherence to
investigation and treatment guidelines, patient outcomes
were favourable compared with other registries.
INTRODUCTION
Shortness of breath is a common and frigh-
tening symptom, which often leads patients
to present to emergency departments
(EDs).1 The recent EuroDEM pilot study
found that 22% of patients had a cardiac
cause for their dyspnoea, with heart failure
(HF) as the most common diagnosis (per-
sonal communication, Laribi, EuroDEM pilot
study, MEMC Congress, Marseilles, France,
September 2013). Approximately 1–2% of
the adult population in developed countries
has HF, with the prevalence rising to ≥10%
among patients over the age of 70.2 The
symptoms of HF progressively deteriorate
over time, and as such it has an important
impact on quality of life. Acute decompensa-
tion often leads to hospital admission.
The AANZDEM study,3 4 built on the
methodology of the EuroDEM study (as
shared by Laribi), aimed to establish how
common shortness of breath was as a
symptom in the ED patient population and
to describe epidemiological features of
patients, distribution of investigations and
treatments as well as diagnosis and clinical
outcomes. This substudy provides a new
insight into ED patients with HF, based on
their presenting symptom of breathlessness.
Strengths and limitations of this study
▪ This is one of the first studies to collect data on
patients with heart failure in the Asia Pacific.
▪ Data were prospectively collected on consecutive
patients with a predefined data dictionary and
using an online database.
▪ Dyspnoea as inclusion criteria is novel and
patient-centred, but may limit comparison with
other heart failure registries.
▪ The diagnosis of heart failure was based on clin-
ician judgement, with limited echo performed in
emergency department, reflecting real-world
practice.
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Several HF registries exist and a recent summary
paper2 highlighted major regional differences in the
severity, aetiology, management and outcomes of
patients with HF in clinical trials and registries. A
paucity of data collected outside North America and
Europe was noted with a call for further data about geo-
graphical variation outside these regions.
To address these unanswered questions, Ambrosy et al2
suggested that a (hospital-based) registry is required
which is geographically representative and employs con-
secutive or intermittently consecutive enrolment and
captures comprehensive and longitudinal data including
hospital course and postdischarge outcomes.
Moreover, leading international organisations have
developed guidelines for the assessment and manage-
ment of patients with acute HF.5 6 Adherence to these
evidence-based guidelines is important but often difﬁ-
cult to measure due to lack of accurate data. This study
will also be able to provide insight in adherence to exist-
ing guidelines.
We aim to describe a cohort of patients attending an
ED in the Asia Paciﬁc region with a principal symptom of
dyspnoea and an ED diagnosis of HF in terms of demo-
graphics, clinical characteristics, investigations ordered,
treatments and patient outcomes (ﬁnal diagnosis, hos-
pital length of stay (LOS) and in-hospital mortality).
METHODS
This is a planned substudy of the AANZDEM study. The
methodology of that study, including deﬁnitions of clin-
ical variables, has been published previously.3 4 In
summary, it was a prospective, descriptive cohort study
conducted in EDs in Australia, New Zealand, Singapore,
Hong Kong and Malaysia of consecutive adult patients
presenting to the ED with dyspnoea as a main symptom
(eg, includes patients who had chest pain as well as dys-
pnoea). Data were collected over three 72-hour periods
in May, August and October 2014 (autumn, winter and
spring in Australasia) and included demographics,
comorbidities, mode of arrival, usual medications, pre-
hospital treatment, initial assessment, ED investigations,
treatment in the ED, ED diagnosis, disposition from ED,
in-hospital outcome and ﬁnal hospital diagnosis.
Participating hospitals also provided data on total ED
presentations and admissions (ward or intensive care
unit (ICU)) for each data collection window.
This substudy includes the patients in the AANZDEM
study with an ED diagnosis of HF. Patients were included
if the principle diagnoses entered by the treating clinician
in the ED information system or in the (electronic)
medical records included HF, decompensated HF, right-
sided HF or acute pulmonary oedema. The primary out-
comes of interest are the epidemiology, investigations
ordered, treatments given and overall outcomes of these
patients. Secondary outcomes were geographical variation.
Analysis was by descriptive statistics, comparisons of
proportions and measures of associations (χ2/Fisher’s
exact test). Non-parametric data were compared using
the Mann-Whitney U test. Analysis programs included
Analyse-It,7 Statistical Package for the Social Sciences
(V.22) and Vassar stats.8 For analysis by region, Australia
and New Zealand data were combined due to the small
number of New Zealand patients (N=28) and compared
against the nine South East Asian EDs. A formal sample
size calculation was not performed, as this is a descriptive
study. Reporting complies with the STROBE guidelines.9
Human research ethics approvals for the overall study,
as well as predeﬁned substudies, were obtained for all sites
according to local requirements. In most jurisdictions,
patient consent for data collection was not required.
RESULTS
Forty-six EDs contributed data on 3044 patients.
Thirty-three sites were located in Australia, four in New
Zealand, four in Hong Kong, three in Singapore and
two in Malaysia. In 2014, the study sites had a combined
annual ED census of 2 886 178 patients.
Demographics and comorbidities
Four hundred and ﬁfty-ﬁve patients (14.9%) had an ED
diagnosis of HF. This represents 0.76% (95% CI 0.69%
to 0.83%) of all ED attendances in the study periods.
Patient characteristics (overall and by geographical
region) are described in table 1. The overall median age
was 79 years (IQR 67–87), half were male and 62%
arrived via ambulance. Patients in South East Asia were
younger (median age 73 vs 81 years, p<0.001) and less
likely to present by ambulance (52% vs 67%, p=0.002).
Common comorbidities included hypertension (72%),
previous diagnosis of HF (57%), ischaemic heart disease
(53%), hyperlipidaemia (47%), diabetes (43%) and pre-
vious atrial ﬁbrillation (AF; 40%).
Patients in South East Asia were signiﬁcantly less likely
to have a history of HF (44% vs 57%, p=0.003), previous
AF (30% vs 40%, p=0.004), valvular disease (p<0.001),
chronic obstructive pulmonary disease (COPD; p<0.001)
or active malignancy (p=0.004) as comorbidities.
Medications
Common regular medications patients were prescribed
before presentation are also described in table 1 and
included: diuretics (62%), statins (52%), antiplatelet
agents (50%), β-blockers (49%) and ACE inhibitors or
aldosterone receptor antagonists (ACEi/angiotensin
receptor blocker (ARB); 48%). Patients from the South
East Asian countries had a signiﬁcantly lower use of
diuretics (54%) and ACEi/ARB (39%), in line with the
lower proportion of patients with a history of HF in
these countries.
Clinical features
Examination ﬁndings are shown in table 2. Overall, on
presentation to ED, 53% of patients had a systolic blood
pressure over 140 mm Hg and three-quarters of the
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Table 1 Patient characteristics: overall, by region and by season
Overall By region
p ValueOverall (N=455) Australia and NZ (N=312) SE Asia (N=143)
Demographics
Age (years, median, IQR) 79 (67–87) 81 (69–88) 73 (63–82) <0.001
Gender (N, % male, 95% CI) 227; 50% (45% to 55%)
Missing data=1
149; 48% (43% to 53%)
Missing data=0
78; 55% (47% to 63%)
Missing data=1
0.12
Ambulance arrival (N, %,
95% CI)
280; 62% (58% to 67%)
Missing data=6
67% (62% to 73%)
Missing data=6
52% (44% to 60%)
Missing data=0
0.002
Comorbidities N, % (95% CI) N, % (95% CI) N, % (95% CI)
Hypertension 327; 72% (68% to 76%)
Missing data=1
221; 71% (66% to 76%)
Missing data=1
106; 74% (66% to 81%)
Missing data=0
0.50
Previous heart failure 256; 57% (52% to 61%)
Missing data=2
193; 62% (57% to 67%)
Missing data=2
63; 44% (36% to 52%)
Missing data=0
0.0003
IHD 239; 53% (48% to 57%)
Missing data=1
161; 52% (46% to 57%)
Missing data=1
78; 55% (46% to 62%)
Missing data=0
0.58
Dyslipidaemia 212; 47% (42% to 52%)
Missing data=4
147; 48% (42% to 53%)
Missing data=4
65; 45% (38% to 54%)
Missing data=0
0.65
Diabetes 194; 43% (39% to 48%)
Missing data=4
131; 43% (37% to 48%)
Missing data=4
63; 44% (36% to 52%)
Missing data=0
0.76
Prior AF 180; 40% (35% to 44%)
Missing data=3
137; 44% (39% to 50%)
Missing data=3
43; 30% (23% to 38%)
Missing data=0
0.004
Renal impairment 127; 28% (24% to 33%)
Missing data=5
86; 28% (23% to 33%)
Missing data=5
41; 29% (22% to 37%)
Missing data=0
0.88
COPD 83; 18% (15% to 22%)
Missing data=5
77; 25% (21% to 30%)
Missing data=5
6; 4% (2% to 9%)
Missing data=0
<0.0001
Valvular disease 69; 15% (12% to 18%)
Missing data=5
61; 20% (16% to 25%)
Missing data=5
6; 4% (2% to 9%)
Missing data=0
<0.0001
Anaemia 57; 13% (10% to 16%)
Missing data=5
34; 11% (8% to 15%)
Missing data=5
23; 16% (11% to 23%)
Missing data=0
0.13
Smoker 35; 8% (6% to 11%)
Missing data=5
27; 9% (6% to 12%)
Missing data=5
8; 6% (3% to 11%)
Missing data=0
0.23
Active malignancy 37; 8% (6% to 11%)
Missing data=4
33; 11% (8% to 15%)
Missing data=4
4; 3% (1% to 7%)
Missing data=0
0.004
Prior PE 17; 4% (2% to 6%)
Missing data=5
15; 5% (3% to 8%)
Missing data=5
2; 1% (0.4% to 5%)
Missing data=0
0.07
Usual medications N, % (95% CI) N, % (95% CI) N, % (95% CI)
Diuretic 280; 62% (57% to 66%)
Missing data=2
203; 65% (60% to 71%)
Missing data=2
77; 54% (46% to 62%)
Missing data=0
0.02
Statin 237; 52% (48% to 57%)
Missing data=1
161; 52% (46% to 57%)
Missing data=1
76; 53% (45% to 61%)
Missing data=0
0.78
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Table 1 Continued
Overall By region
p ValueOverall (N=455) Australia and NZ (N=312) SE Asia (N=143)
Antiplatelet agent 226; 50% (45% to 54%)
Missing data=2
148; 48% (42% to 53%)
Missing data=2
78; 55% (46% to 62%)
Missing data=0
0.18
β-blocker 224; 49% (45% to 54%)
Missing data=2
160; 52% (46% to 57%)
Missing data=2
64; 45% (37% to 53%)
Missing data=0
0.18
ACE inhibitor/angiotensin
receptor blocker
217; 48% (43% to 53%)
Missing data=3
161; 52% (47% to 58%)
Missing data=3
56; 39% (32% to 47%)
Missing data=0
0.01
Long-acting oral anticoagulant 127; 28% (24% to 32%)
Missing data=3
105; 34% (29% to 39%)
Missing data=3
22; 15% (10% to 22%)
Missing data=0
<0.0001
Calcium channel blocker 112; 25% (21% to 29%)
Missing data=3
74; 24% (20 to 29%)
Missing data=3
38; 27% (20 to 34%)
Missing data=0
0.54
Inhaled β-sympathomimetic 103; 23% (19% to 27%)
Missing data=4
85; 28% (23% to 33%
Missing data=4
18; 13% (8% to 19%)
Missing data=0
0.0004
Nitrate 85; 19% (16% to 23%)
Missing data=4
51; 17% (13% to 21%)
Missing data=4
34; 24% (18% to 31%)
Missing data=0
0.07
Insulin 66; 15% (12% to 18%)
Missing data=4
46; 15% (11% to 19%)
Missing data=4
20; 14% (9% to 21%)
Missing data=0
0.79
Aldosterone antagonist 54; 12% (9% to 15%)
Missing data=3
39; 13% (9% to 17%)
Missing data=3
15; 10% (6% to 17%)
Missing data=0
0.51
Oral corticosteroid 22; 5% (3% to 7%)
Missing data=5
17; 6% (3% to 9%)
Missing data=5
5; 4% (2% to 8%)
Missing data=0
0.35
Home oxygen 16: 4% (2% to 6%)
Missing data=4
14; 5% (3% to 7%)
Missing data=4
2; 1% (0.5% to 5%)
Missing data=0
0.09
Data adjusted for missing data.
AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease; NZ, New Zealand; PE, pulmonary embolism; SE Asia, South East Asia, combined data from
Malaysia, Hong Kong and Singapore.
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Table 2 Examination findings, testing and pathology findings, overall and by region
Overall By region
p ValueOverall (N=455) Australia and NZ (N=312) SE Asia (N=143)
Examination findings in ED
Pulse (bpm) 86 (72–102)
Missing data=6
85 (71–102)
Missing data=4
90 (73–103)
Missing data=2
0.36
SBP (mm Hg, IQR) 143 (125–166)
Missing data=8
141 (122–160)
Missing data=7
144 (128–172)
Missing data=1
0.08
Respiratory rate (per min, IQR) 24 (20–28)
Missing data=4
24 (20–30)
Missing data=4
21 (19–26) 0.0007
Oxygen saturation on air (%, where known, IQR) 95% (92–98%)
Missing data=113
94% (90–96%)
Missing data=76
97% (95–99%)
Missing data=37
<0.0001
Oxygen saturation on oxygen (%, where known
excludes patients with SpO2 on air, IQR)
97% (95–99%)
Missing data=5
97% (94–99%)
Missing data=4
98% (97–100%)
Missing data=1
<0.0001
Peripheral oedema (N, %, 95% CI) 301; 77% (72% to 81%)
Missing data=63
204; 76% (71% to 81%)
Missing data=45
97; 78% (70% to 84%)
Missing data=18
0.68
SBP>140 mm Hg (N, %, 95% CI) 235; 53% (48% to 57%)
Missing data=8
156; 52% (46% to 57%)
Missing data=7
79; 56% (47% to 64%)
Missing data=1
0.41
SBP>160 mm Hg (N, %, 95% CI) 126; 28% (24% to 33%)
Missing data=8
76; 25% (20% to 30%)
Missing data=7
50, 35% (28% to 43%)
Missing data=1
0.03
SpO2<90%, (on air or oxygen) (N, %, 95% CI) 74; 16% (13% to 20%)
Missing data=5
56; 18% (14% to 23%)
Missing data=4
8; 6% (3% to 11%)
Missing data=1
0.007
Respiratory rate >30/min, (N, %, 95% CI) 76; 17% (14% to 21%
Missing data=4
63; 20% (16% to 25%)
Missing data=4
16; 12% (7% to 17%)
Missing data=0
0.02
Chest findings in ED N, % (95% CI) N, % (95% CI) N, % (95% CI)
Basal crepitations 233; 53% (49% to 58%)
Missing data=19
146; 49% (44% to 55%)
Missing data=15
87; 63% (54% to 70%)
Missing data=4
0.01
Widespread crepitations 86; 20% (16% to 24%)
Missing data=19
67; 23% (18% to 28%)
Missing data=15
19; 14% (8% to 20%)
Missing data=4
0.05
Testing ordered in ED N, % (95% CI) N, % (95% CI) N, % (95% CI)
Chest radiograph 429; 95% (92% to 96%)
Missing data=0
292; 94% (90% to 96%)
Missing data=0
137; 96% (91% to 98%)
Missing data=0
0.48
Lung ultrasound in ED 3; 0.7% (0.2% to 2%)
Missing data=0
1; 0.3% (0.06% to 2%)
Missing data=0
1% (0.4% to 5%)
Missing data=0
0.19
Echocardiography in ED 10; 2% (1% to 4%)
Missing data=2
7; 2% (1% to 5%)
Missing data=2
3; 2% (0.7% to 6%)
Missing data=0
0.91
Electrolytes 393; 86% (83% to 89%)
Missing data=0
299; 98% (96% to 98%)
Missing data=0
94; 66% (58% to 73%)
Missing data=0
<0.0001
Full blood examination 408; 90% (87% to 92%)
Missing data=0
305; 98% (95% to 99%)
Missing data=0
103; 72% (64% to 79%)
Missing data=0
<0.0001
BNP (N, %, 95% CI) 25; 5% (4% to 8%)
Missing data=0
25; 8% (5% to 12%)
Missing data=0
0; 0% (0% to 2.6%)
Missing data=0
0.001
NT-proBNP 62; 14% (11% to 17%)
Missing data=0
33; 11 (8% to 14%)
Missing data=0
29; 20% (15% to 28%)
Missing data=0
0.008
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Table 2 Continued
Overall By region
p ValueOverall (N=455) Australia and NZ (N=312) SE Asia (N=143)
Natriuretic peptide (either BNP or NT-proBNP) 87; 19% (16% to 23%)
Missing data=0
58; 19% (15% to 23%)
Missing data=0
29; 20% (15% to 28%)
Missing data=0
0.76
Troponin 287; 63% (59% to 67%)
Missing data=0
204; 65% (60% to 70%)
Missing data=0
83; 58% (50% to 66%)
Missing data=0
0.16
C reactive protein 145; 32% (28% to 36%)
Missing data=0
140; 45% (40% to 50%)
Missing data=0
5; 4% (2% to 8%)
Missing data=0
<0.0001
Blood gas analysis 167; 37% (32% to 41%)
Missing data=0
145; 46% (41% to 52%)
Missing data=0
22; 15% (10% to 22%)
Missing data=0
<0.001
Glucose 256; 56% (52% to 61%)
Missing data=0
191; 61% (56% to 66%)
Missing data=0
65: 45% (38% to 54%)
Missing data=0
0.002
D-dimer 11; 2% (1% to 4%)
Missing data=0
11; 4% (2% to 6%)
Missing data=0
0; 0% (0% to 3%)
Missing data=0
0.04
Lactate 125; 27% (24% to 32%)
Missing data=0
108; 35% (30% to 40%)
Missing data=0
17; 12% (8% to 18%)
Missing data=0
<0.0001
Albumin 256; 56% (52% to 61%)
Missing data=0
221; 71% (66% to 76%)
Missing data=0
35; 24% (18% to 32%)
Missing data=0
<0.0001
Pathology findings N, % (95% CI) N, % (95% CI) N, % (95% CI)
Serum sodium concentration <130 mmol/L 18; 4% (3% to 6%)
Missing data=0
15; 5% (3% to 8%)
Missing data=0
3; 2% (0.7% to 6%)
Missing data=0
0.20
Haemoglobin <10 mmol/L 67; 15% (12% to 18%)
Missing data=0
48; 15% (12% to 20%)
Missing data=0
19; 13% (9% to 20%)
Missing data=0
0.57
Serum creatinine >80 µmol/L 313; 69% (65% to 73%)
Missing data=0
229; 73% (68% to 78%)
Missing data=0
84; 59% (51% to 66%)
Missing data=0
0.002
Serum creatinine >150 µmol/L 114; 25% (21% to 29%)
Missing data=0
80; 26% (21% to 31%)
Missing data=0
34; 24% (18% to 31%)
Missing data=0
0.73
Troponin >99th centile for test 173; 38% (34% to 43%)
Missing data=0
123; 39% (34% to 45%)
Missing data=0
50; 35% (28% to 43%)
Missing data=0
0.41
Data adjusted for missing data.
BNP, β natriuretic peptide; bpm, beats per minute; ED, emergency department; NT-proBNP, N-terminal pro β natriuretic peptide; NZ, New Zealand; SBP, systolic blood pressure; SE Asia, South
East Asia, combined data from Malaysia, Hong Kong and Singapore; SpO2, oxygen saturation by pulse oximetry.
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Table 3 Treatment and outcomes, overall and by region
Overall By region
p ValueOverall (N=455) Australia and NZ (N=312) SE Asia (N=143)
Treatment in ED N, % (95% CI) N, %, (95% CI) N, %, (95% CI)
Oxygen 285; 62% (58% to 67%) 186; 60% (54% to 65%) 99; 69% (61% to 76) 0.06
Non-invasive ventilation 56; 12% (10% to 16%) 49; 16% (12% to 20%) 7; 5% (2% to 10%0 0.002
Mechanical ventilation 4; 1% (0.3% to 2%) 2; 0.6% (0.1% to 2.3%) 2; 1% (0.4% to 5%) 0.81
Diuretic
Any 332; 73% (69% to 77%)
Missing data=2
236; 76% (71% to 81%)
Missing data=2
96; 67% (59% to 74%)
Missing data=0
0.06
IV 303; 67% (62% to 71%)
Missing data=2
210; 68% (62% to 73%)
Missing data=2
93; 65% (57% to 72%)
Missing data=0
0.65
Oral 46; 10% (8% to 13%)
Missing data=2
40; 13% (10% to 17%)
Missing data=6
6; 4% (2% to 9%)
Missing data=0
0.007
Nitrate
Any 115; 25% (22% to 30)
Missing data=2
72; 23% (19% to 28%)
Missing data=2
43; 30% (23% to 38%)
Missing data=0
0.15
IV bolus 1; 0.2% (0.04% to 1%)
Missing data=2
1; 0.3% (0.06% to 2%)
Missing data=2
0; 0% (0% to 3%)
Missing data=0
0.69
IV infusion 31; 7% (5% to 10%)
Missing data=3
16; 5% (3% to 8%)
Missing data=3
15; 10% (6% to 17%)
Missing data=0
0.06
Sublingual/transdermal/oral 89; 20% (16% to 24%)
Missing data=4
58; 19% (15% to 24%)
Missing data=4
31; 22% (16% to 29%)
Missing data=0
0.56
Inotrope/vasopressor 5; 1% (0.5% to 3%)
Missing data=5
4; 1% (0.5% to 3%)
Missing data=5
1; 0.7% (0.1% to 4%)
Missing data=0
0.92
Morphine 16; 4% (2% to 6%)
Missing data=6
14; 5% (3% to 8%)
Missing data=6
2; 1% (0.4% to 5%)
Missing data=0
0.16
Anticoagulant 31; 7% (5% to 10%)
Missing data=5
26; 8% (6% to 12%)
Missing data=5
5; 4% (2% to 8%)
Missing data=0
0.08
Antiplatelet agent 40; 9% (7% to 12%)
Missing data=5
28; 9% (6% to 13%)
Missing data=5
12; 8% (5% to 14%)
Missing data=0
0.92
Antibiotic 71; 16% (13% to 19%)
Missing data=5
59; 19% (15% to 24%)
Missing data=5
12; 8% (5% to 14%)
Missing data=0
0.005
Systemic corticosteroid 26; 6% (4% to 8%)
Missing data=5
25; 8% (6% to 12%)
Missing data=5
1; 0.7% (0.1% to 4%)
Missing data=0
0.003
Inhaled bronchodilator 58; 13% (10% to 16%)
Missing data=5
49; 16% (12% to 20%)
Missing data=5
9; 6% (3% to 11%)
Missing data=0
0.007
Treatment combinations N, % (95% CI) N, % (95% CI) N, % (95% CI)
Diuretic+nitrate (any route) 97; 21% (18% to 25%)
Missing data=2
59; 19% (15% to 24%)
Missing data=2
38; 27% (20% to 34%)
Missing data=0
0.09
Diuretic+inhaled bronchodilator 47; 10% (8% to 14%)
Missing data=5
41; 13% (10% to 18%)
Missing data=5
6; 4% (2% to 9%)
Missing data=0
0.005
Diuretic+antibiotic 58; 13% (10% to 16%)
Missing data=5
48; 16% (12% to 20%)
Missing data=5
10; 7% (4% to 12%)
Missing data=0
0.02
Continued
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Table 3 Continued
Overall By region
p ValueOverall (N=455) Australia and NZ (N=312) SE Asia (N=143)
Diuretic+nitrate (any route)+antibiotic 18; 4% (3% to 6%)
Missing data=6
15; 5% (3% to 8%)
Missing data=6
3; 2% (0.7% to 6%)
Missing data=0
0.25
Diuretic+inhaled bronchodilator+systemic
corticosteroid
13; 3% (2% to 5%)
Missing data=5
13; 4% (2% to 7%)
Missing data=5
0; 0% (0% to 3%)
Missing data=0
0.03
Diuretic+inhaled bronchodilator+systemic
corticosteroid+antibiotic
8; 2% (1% to 4%)
Missing data=5
8; 3% (1% to 5%)
Missing data=5
0; 0% (0% to 3%)
Missing data=0
0.12
Outcome N, % (95% CI) N, % (95% CI) N, % (95% CI)
Admission to hospital ward (including ICU
and interhospital transfers for admission)
392; 86% (83% to 89%)
Missing data=1
265; 85% (81% to 89%)
Missing data=1
127; 89% (83% to 93%)
Missing data=0
0.37
ICU admission 19; 4% (3% to 7%)
Missing data=1
13; 4% (3% to 7%)
Missing data=1
6; 4% (2% to 9%)
Missing data=0
0.81
ED short stay unit management (excludes
hospital ward admission)
10; 2% (1% to 4%)
Missing data=1
6; 2% (1% to 4%)
Missing data=1
4; 3% (1% to 7%)
Missing data=0
0.81
Length of stay for patients admitted to
hospital (days, median, IQR)
6, 4 to 9
Missing data=22
6, 3 to 9
Missing data=22
6, 3 to 8
Missing data=0
0.44
Died in ED 2; 0.5% (0.1% to 2%)
Missing data=1
2; 0.6% (0.2% to 2%)
Missing data=1
0; 0% (0% to 3%)
Missing data=0
0.58
In-hospital mortality for patients admitted to
ward including ICU
20; 5% (3% to 7%)
Missing data=22
14; 6% (3% to 9%)
Missing data=22
6; 5% (2% to 10%)
Missing data=0
0.92
Data adjusted for missing data.
Nitrate: some patients had more than one route of administration.
ED, emergency department; ICU, intensive care unit; IV, intravenous; NZ, New Zealand; SE Asia, South East Asia, combined data from Malaysia, Hong Kong and Singapore.
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patients had chest ﬁndings of ﬂuid overload on ausculta-
tion (73%) or peripheral oedema (77%). The cohort of
South East Asian patients was less likely to have oxygen
saturations (on air or oxygen) <90% (6% vs 18%,
p=0.007) or a respiratory rate >30/min (12% vs 20%,
p=0.02) on presentation.
Investigations
Ordered investigations are shown in table 2. Chest radio-
graph (chest X-ray) was performed in 95%, troponin
concentration in 63%, blood gas (either arterial or
venous) in 37%, C reactive protein (CRP) in 32%, natri-
uretic peptide (NP) level (N-terminal pro β natriuretic
peptide (NT-proBNP) or BNP) in 19% and D-dimer in
2%. Lung ultrasound (<1%) and echocardiography
(2%) were uncommonly conducted in ED. Overall,
anaemia (haemoglobin <10 mmol/L, 15%) and hypona-
traemia (sodium concentration <130 mmol/L, 4%) were
relatively infrequent ﬁndings.
South East Asian sites had signiﬁcantly lower rates of
ordering both routine tests (such as full blood count (72%
vs 98%, p<0.001) and electrolytes (66% vs 98%, p<0.001))
as well as tests targeting more speciﬁc conditions (such as
blood gas (15% vs 46%, p<0.001), CRP (4% vs 45%,
p<0.001) and lactate (12% vs 35%, p<0.001)).
Treatment
Table 3 describes treatment modalities used, which
included non-invasive ventilation (12%), diuretics (73%)
and nitrates (25%). In line with the very low number of
patients with a systolic blood pressure <90 mm Hg, the
use of inotropes was infrequent overall (<1%). One
hundred and ﬁfty-ﬁve (34%, 95% CI 30% to 39%)
patients received antibiotics, inhaled β-agonists or corti-
costeroids, suggesting either mixed disease or diagnostic
uncertainty. Treatment combinations covering for more
conditions than HF alone were less common in South
East Asian EDs.
Outcomes
Outcomes are summarised in table 3. Most patients
(86%) were admitted to hospital with a median LOS of
6 days (IQR 4–9), including a 4% admission rate to the
ICU. Very few patients (2%) were admitted to an ED
short stay setting. This admission rate pattern, including
LOS, was similar across geographic areas. Hospital diag-
nosis was concordant with ED diagnosis in 81% of cases,
with discordant cases mainly accounted for by hospital
discharge diagnosis of COPD (4%), pulmonary infection
(4%) and acute coronary syndrome (3%). In-hospital
mortality (including deaths in ED) was 5.1% (95% CI
3.3% to 7.7%) and was similar between regions.
DISCUSSION
Summary
In the Asia Paciﬁc region, HF is a common diagnosis in
patients presenting to the ED with a principal symptom
of dyspnoea with the majority (86%) of these patients
admitted to hospital, a proportion in keeping with other
international cohorts.10 This unique study of breathless
patients in the ED highlights some signiﬁcant regional
differences in the demographic and clinical features on
presentation, ordered investigations and treatment of
patients with acute HF.
Comparison with existing literature
The outcomes of patients with HF compare favourably
with other registries, despite our cohort being older and
compliance with certain features of evidence-based
guidelines seemingly suboptimal. The median LOS was
6 days, at the lower end of ranges reported by other
studies of between 3.5 and 20 days.11 12 In-hospital mor-
tality was 5.1%, at the lower end of the reported median
range of 4–30%.2 There was infrequent use of ED short
stay admission for this patient group, reﬂecting an
almost dichotomous disposition pathway (inpatient
admission vs discharge); however, others have suggested
that up to half of the ED patients with HF could be
safely discharged after a brief period of observation.13
This suggests a missed opportunity in our cohort where
short stay wards in ED are usually available. It is possible
that a number of inpatient admissions could have been
avoided if appropriate local short stay pathways existed.
With a median age of 79 years, patients in our cohort
were older than patients in the three largest (US) regis-
tries (ADHERE; OPTIMIZE-HF; GWTG-HF 72–74
years)14–17 and several of the smaller (European and
Japanese) registries (EHFS, ESC-HF, IN-HF, EFICA,
RO-AHFS, ATTEND; ranging from 69 to 73 years).2
Gender distribution was similar to the three US
registries.
Overall patient demographics and comorbidities were
comparable with those reported in existing HF registries
in the USA and Europe; however, there was considerable
regional variation for these variables within our cohort.
South East Asian patients were younger than their
Australian and New Zealand counterparts; however, they
had similar rates of cardiovascular comorbidities (dia-
betes, ischaemic heart disease, hypertension, dyslipidae-
mia). Lower rates of pre-existing HF, valvular disease and
COPD in the South East Asian patients may be due to
their being a median 8 years younger. Our ﬁnding is
consistent with previous data showing that South East
Asian patients with HF are younger, suggesting that eth-
nicity may play a part.18 Differences in mode of presen-
tation between South East Asian patients and their
Australian and New Zealand counterparts, with less
ambulance usage in South East Asian patients, may be
due to the younger age, fewer comorbidities and lower
rates of hypoxia or tachypnoea, or to regional differ-
ences in ambulance availability, use and cost. Despite
these differences, admission rates and hospital LOS were
similar in the different geographical regions.
Our ﬁndings of one in ﬁve patients overall having an
NP ordered is lower than that expected from acute HF
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guidelines6 and difﬁcult to compare to other cohorts
due to a lack of data collection or large number of
missing data in those cohorts. The National Institute for
Health and Care Excellence (NICE) guidelines for
acute HF5 recommends using NT-proBNP in patients
with suspected new-onset acute HF. Although more than
half of our cohort had a previous diagnosis of HF, the
overall use of NPs is lower than recommended. It is pos-
sible that NPs were mainly used for patients in whom
there was diagnostic uncertainty. Some hospitals have
test ordering protocols that defer this test ordering to
inpatient teams. Using NPs to titrate management in
patients with chronic HF is associated with improved
mortality,19 20 but it is unclear if the timing of this meas-
urement matters (ED vs inpatient). Although our study
highlights a gap between guidelines and implementation
of evidence-based testing in clinical care, it raises a ques-
tion about the speciﬁcity and applicability of these
guidelines to our ED setting, since the outcomes of our
study compare favourably despite the low NP ordering
rates.
There were signiﬁcant differences in the number of
investigations requested for each patient assessed with
an ED diagnosis of HF. Overall, patients presenting to
Australian EDs had the most pathology tests ordered,
with South East Asian EDs the least. This could possibly
be explained by the South Asian cohort being younger,
having fewer comorbidities, and as such, alternative diag-
noses may not have needed to be entertained as fre-
quently. Other regional differences in test ordering
could be explained by different levels of perceived medi-
colegal risk, varying approaches to investigations either
clinically or logistically inﬂuenced by training pro-
grammes, time targets, testing bundles, insurance
systems and out-of-pocket expenses. Lower levels of
anaemia and hyponatraemia were detected in compari-
son to other registries and may be due to differences in
the chosen cut-offs deﬁning abnormalities (we did not
include mild hyponatraemia (130–135 mmol/L)], eg).
Overall, over one-third of patients (37%) had a blood
gas ordered, where approximately one-sixth of patients
were hypoxic (16%). We cannot comment on whether
blood gases were ordered for assessment of ventilation
or for other reasons such as the (bedside) assessment of
acid–base disorders or electrolyte status.
Three-quarters of patients were treated with diuretics
and one-quarter with nitrates, with relatively little geo-
graphical variation. Diuretic treatment was less com-
monly initiated compared with other registries (73% vs
76–92%—ADHERE 92%, EHFS II—82%, ATTEND
76%, ALARM 90%)2 and less than guidelines would
suggest—since they are recommended as ﬁrst-line treat-
ment.5 21 The proportion of nitrates used is somewhat
more in line with guidelines, which suggest that nitrates
should not be routinely offered5 or as an adjunct if
hypotension is absent.6
Despite the seemingly suboptimal adherence to com-
ponents of the guidelines in terms of investigations (NP
ordering) and treatments (diuretic use), patient out-
comes are favourable compared with other registries,
which raises questions about the utility of the existing
guidelines in undifferentiated patients presenting to the
ED with dyspnoea. Other treatments and treatment com-
binations did vary considerably, with South East Asian
patients receiving fewer antibiotics, β-agonists and corti-
costeroids. As outlined previously, this is possibly a func-
tion of this cohort being younger with more commonly
single-system disease. Overall, one in six patients
received antibiotics (16%), which may be a reﬂection of
the proportion of patients being judged by the treating
clinician to have mixed disease (including infection),
although we are unable to comment on the appropriate-
ness of its use.
Very few (∼1%) patients received inotropic support
compared with registries reporting use between 15%
and 30% (ADHERE 15%, EHFS II 30%, ATTEND 18%,
ALARM 22%).2 This ﬁnding suggests regional practice
variation that seems unlikely to be due to difference in
HF severity (since our cohort was older with similar clin-
ical features and comorbidities). This may be partially
explained by the 19% of patients with a discordant ED
and hospital diagnosis. Another possible explanation is
that since the patients in our cohort had dyspnoea as a
main symptom, they were more likely to have HF with
preserved ejection fraction (EF) and, as such, less likely
to require inotropic support. In any case, this difference
in inotrope use could have implications for interpreta-
tions of our outcomes, since even short-term inotrope
use has been associated with increased mortality.22
Strengths and limitations
The study sites were located in the South East Asia/
Australasia geographical area and may not be generalis-
able to other regions. The results of the South East Asia
cohort were based on nine sites in three countries
(Hong Kong, Singapore and Malaysia), and our ﬁnding
may not be able to be extrapolated to other countries in
South East Asia.
Although we collected data prospectively from con-
secutive patients presenting with dyspnoea, it is possible
that patients with HF were missed due to the design of
the overarching study which focused on including
patients with dyspnoea as a main symptom. Over 90% of
patients with HF have dyspnoea,23 but it is possible that
a proportion of patients with HF may have presented
without dyspnoea—and rather chest pain, fatigue or per-
ipheral oedema.
The ED diagnosis of HF was based on clinician judge-
ment. Since there is no gold standard for the diagnosis
of HF, clinician diagnosis of HF based on the history,
signs of ﬂuid overload on physical examination and/or
chest radiograph (± response to HF therapy) are often
an accepted standard.24 The agreement between ED
and ﬁnal hospital diagnosis was 81%, suggesting good
accuracy of diagnosis. In some of the discordant cases,
where the primary hospital diagnosis was COPD (4%),
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pulmonary infection (4%) or acute coronary syndrome
(3%), HF may have been a secondary process. Targeted
use of lung ultrasound25 and/or bedside echocardiog-
raphy and NPs could possibly further improve the diag-
nostic accuracy in ED.26
Echocardiography was rarely performed in the ED, in
line with the recent recommendation that urgent echo
in the ED is only required when the patient is in cardio-
genic shock.27 As a result, data on EF were not collected
in the vast majority of patients and we cannot comment
on proportions of patients with preserved or reduced
EF. This makes interpretation regarding adherence to
some components of the guidelines related to EF difﬁ-
cult, but it highlights the scope for inclusion of speciﬁc
ED populations with both preserved and reduced EF in
future guidelines.
CONCLUSION
This study on patients with HF provides a novel insight
in several ways, highlighting regional variation in demo-
graphics, investigations and treatment in a cohort of
patients from a previously under-reported geographical
area, the Asia Paciﬁc region. Overall, despite an older
cohort, and a seemingly suboptimal adherence to the
guidelines in terms of investigations and treatments,
patient outcomes are favourable compared with other
registries.
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